Regeneron Pharmaceuticals (REGN) Return on Sales (2009 - 2026)

Regeneron Pharmaceuticals' Return on Sales history runs 18 years deep, the most recent figure standing at 0.0% for Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales eased to 0.0% in Q1 2026 per REGN's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.19% in Q1 2022 and bottomed at 0.0% in Q1 2026.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.02%.
• Across the five-year window, Return on Sales grew 19 bps in 2022 and dropped 19 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.12% in 2022, then plunged by 97 bps to 0.0% in 2023, then fell by 28 bps to 0.0% in 2024, then fell by 10 bps to 0.0% in 2025, then slipped by 7 bps to 0.0% in 2026.
• Per Business Quant, the three latest REGN Return on Sales figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).